NDAORALTABLET
Approved
Mar 1982
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
4
Data completeness
3/8 — Basic
SEROPHENE (clomiphene citrate) by Rubicon Biotechnology is clinical pharmacology action clomiphene citrate is a drug of considerable pharmacologic potency. First approved in 1982.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SEROPHENE (clomiphene citrate) is an oral small-molecule selective estrogen receptor modulator (SERM) indicated for anovulatory infertility in women desiring pregnancy. It works by competing with estrogen for receptor-binding sites in the hypothalamus and pituitary, triggering a cascade of gonadotropin release that initiates ovulation. The drug has mixed estrogenic and antiestrogenic properties that together stimulate follicular development and the preovulatory LH surge.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure; brand team likely focused on lifecycle management and transition planning rather than growth initiatives.
Mechanism of Action
CLINICAL PHARMACOLOGY Action Clomiphene citrate is a drug of considerable pharmacologic potency. With careful selection and proper management of the patient, clomiphene citrate has been demonstrated to be a useful therapy for the anovulatory patient desiring pregnancy. Clomiphene citrate is capable…
Worked on SEROPHENE at Rubicon Biotechnology? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.